Post-traumatic stress disorder focused Tonix Pharmaceuticals top Nasdaq gainer

(Before It's News)

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP), which is working on a treatment for posttraumatic stress disorder (PTSD), was top gainer on the Nasdaq exchange in New York.

Shares in the drug developer added almost 40% to stand at $5.77 each as it revealed it will present at The MicroCap Conference on April 4 this year in the city.

Chief executive Seth Lederman  will give a corporate update and an overview of Tonix’s PTSD clinical program.

Its candidate TNX-102 SL has significantly recently been granted what is called ‘Breakthrough Therapy’ designation by the all powerful US FDA for the treatment of PTSD.

This month, Tonix dosed the first patient for a 12-week placebo-controlled Phase 3 clinical study evaluating TNX-102 SL 5.6 mg, in military-related PTSD.

The interim analysis of the HONOR study is expected in the first half of 2018 and topline results are expected in the second half of 2018.

Story by ProactiveInvestors

• Audit The Fed Bill Pases House Committee!
• Lite Access making big strides with revolutionary connectivity technology
• The People Want Pot —The States Want Profits
• Enertopia getting inquiries from lithium producers after bench test press release
• Aligning Multiple Timeframes
• Lite Access using revolutionary technology in BC network deal
• Should Brexit be negotiated between some Brussels divorce lawyers blithely ignoring what the divorcees might want?
• Did the Top for the First Half of 2017 Just Hit?
• This Week’s ETF Launches: How about “Giving Quality A Squeeze?”
• Strong markets struggling at breakout levels of late